Director Cheryl Pegus buys Boston Scientific (BSX) shares in open-market trade

Rhea-AI Filing Summary

Boston Scientific director Cheryl Pegus bought 1,770 shares of common stock in an open-market transaction. The purchase occurred at a weighted average price of about $56.49 per share, across multiple trades priced between $56.49 and $56.5009. After this transaction, she directly owns 1,770 shares.

Insider Trade Summary

Net Buyer: 1,770 shares ($99,987)

Net Buy 1 txn

Insider Pegus Cheryl

Role null

Bought 1,770 shs ($100K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,770	$56.49	$100K

Holdings After Transaction: Common Stock — 1,770 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares purchased: 1,770 shares Weighted average price: $56.49 per share Post-transaction holdings: 1,770 shares +2 more

5 metrics

Shares purchased 1,770 shares Open-market purchase of Boston Scientific common stock

Weighted average price $56.49 per share Average purchase price across multiple transactions

Post-transaction holdings 1,770 shares Total direct ownership after the reported transaction

Price range $56.49–$56.5009 per share Range of individual trade prices in the purchase

Transaction date May 20, 2026 Date of the open-market purchase

Key Terms

open-market purchase, weighted average purchase price, Form 4

3 terms

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average purchase price financial

"Represents the weighted average purchase price."

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pegus Cheryl

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MASSACHUSETTS 01752-1234

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/20/2026		P		1,770	A	$56.49(1)	1,770	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $56.49 to $56.5009, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

	/s/ Susan Thompson, Attorney-in-Fact	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Boston Scientific (BSX) disclose for Cheryl Pegus?

Boston Scientific reported that director Cheryl Pegus made an open-market purchase of 1,770 shares of common stock. The transaction increases her direct ownership stake and is disclosed on a Form 4 insider trading report filed with regulators.

How many Boston Scientific (BSX) shares did Cheryl Pegus buy and at what price?

Cheryl Pegus bought 1,770 Boston Scientific common shares. The weighted average purchase price was about $56.49 per share, with individual trades executed in a narrow range between $56.49 and $56.5009 according to the Form 4 disclosure.

Is Cheryl Pegus’ Boston Scientific (BSX) trade an open-market purchase?

Yes. The Form 4 identifies the transaction with code “P,” meaning an open-market or private purchase. The filing describes it as an open-market purchase of Boston Scientific common stock at a weighted average price around $56.49 per share.

What is Cheryl Pegus’ Boston Scientific (BSX) ownership after this Form 4 transaction?

Following the reported transaction, Cheryl Pegus directly owns 1,770 shares of Boston Scientific common stock. The Form 4 lists this figure as her total direct holdings after completing the open-market purchase disclosed in the filing.

How was the purchase price for Cheryl Pegus’ Boston Scientific (BSX) shares determined?

The filing states the reported price is a weighted average purchase price. Shares were bought in multiple transactions at prices ranging from $56.49 to $56.5009, and detailed trade-by-trade pricing is available to regulators or shareholders on request.